Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
NCT ID: NCT00476242 Phase: PHASE2 Status: COMPLETED Enrollment: 82 Completion: 2011-08
Conditions
Opioid Dependence, Heroin Dependence
Interventions
Vivitrol, memantine
Summary
Prospective participants will undergo a screening process at the clinic to determine eligibility. After screening, eligible patients will complete an 8-day inpatient detoxification, followed by a 12-week outpatient phase. Patients will be randomly assigned to one of two conditions (1) Naltrexone + Placebo; (2) Naltrexone + Memantine 20 mg bid. Long-acting, injectable form of naltrexone (Vivitrol) will be administered once per month (the total of three injections) while memantine or placebo will be taken daily. In addition, patients will receive twice weekly psychosocial intervention that will include motivational interviewing and cognitive-behavioral relapse prevention. The outpatient treatment will also consist of 3 weekly visits to the clinic in which patients will receive counseling to help maintain abstinence and improve compliance with study medication.
Primary Outcome
Opiate Use Measured by Urine Toxicology Results